Domestic 2nd ADC drug approved for market treatment of two types of lymphoma!

Yesterday, Takeda China announced that its targeted innovative drug injection vibtoxidaner (Anshili ®) was officially approved by the State Drug Administration for the treatment of adult CD30-positive recurring or refractory systemic interdational large cell lymphoma (sALCL) and recurring or refractory classic Hodgkin's lymphoma (cHL).Injection with vibtoxi monoantigen is made up of monoclonal antibodies targeting CD30, which are connected to a cytotoxic drug (monomedrone aurestatin E, MMAE) that inhibits micro-tubes and stabilizes the presence in the blood and precisely kills tumor cells expressing CD30. The product is clinically experienced, the real world evidence-based basis is sufficient, the efficacy has long been verified. Previously, the National Comprehensive Cancer Network (NCCN) guidelines have recommended Vibtoxi monoantigen as a standard treatment, and the Chinese Society of Clinical Oncology (CSCO) guidelines have included it in clinical options.The approval of vibtoxi monoantigen resistance for injection in China is based on data from three clinical studies, SG035-0004, SG035-0003, and C25007:In the SG-035-0004 study, 97% of the 58 patients had relapsed or recurring systemic mesolytic large cell lymphoma for recurring or recurring interstitocid lymphoma Patients can achieve tumor reduction, their five-year survival rate increased to 60%;in the SG035-0003 study, 94% of patients with relapsed or incurable classic Hodgkin's lymphoma achieved tumor reduction, the total survival of the neutral (OS) increased from a historical 27.6 months to 40.5 months,in C2507 study Objective remission rate (ORR) was 50% (95% CI, 37: 63%) in patients with relapsed or incurable classic Hodgkin's lymphoma (n-60) who had received at least one chemotherapy course in the past and started vibtoxi monotherapy.Lymphoma is a malignant tumor that originates in the lymphatic hemaggioma system and is commonly known as the "lymphoma family" of more than 70 different subtypes. At present, lymphoma is one of the top ten malignant tumors in China. Data show that about 93,000 people in China are diagnosed with lymphoma each year, and more than 50,000 people die from the cancer each year. At present, the treatment methods for relapsed or recurring systemic mesolytic large cell lymphoma and classic Hodgkin's lymphoma are limited, and the survival status of patients is not optimistic.
(Takeda China)